Pfizer has acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the company. AM‐Pharma is a privately held Dutch biopharma company focused on the development of recombinant human Alkaline Phosphatase (recAP) for inflammatory diseases.   Pfizer has made an upfront payment of $87.5 million for the minority interest and exclusive option, with additional potential payments of up to $512.5 million upon the potential launch of any product from this agreement.   P...